Structure Encountered

Triveni Bio

Develops genetics-informed antibody therapeutics for immune and inflammatory barrier diseases

Triveni starts Phase 1 of TRIV-573, a KLK5/7×IL-13 bispecific for atopic dermatitis, while the protease-only TRIV-509 reads out at end of 2026. Two AD assets, two mechanisms, $200M+ funded.

SIGNAL·Phase 1 first-in-human dosing·First healthy volunteers dosed with TRIV-573, half-life extended KLK5/7×IL-13 bispecific; Phase 2 proof-of-concept in moderate-to-severe atopic dermatitis planned later in 2026·SCORE 78·19 MAY 2026 · 12:47 UTC

● CAPTURE — IMAGE INCOMINGFRAME 01 / 01

Structure Triveni Bio, captured by Voyager

STRUCT. / TRIVENI BIO

/ Watertown, Massachusetts, United States

CAPT. / 19.05.26 12:47:05Z

SIGNAL / 78 / 100

Image relayed by The Biotech Voyager during pass over structure Triveni Bio. Resolution as transmitted.

001Vital Statistics

DATA LOCKED

Designation

Triveni Bio

Coordinates

Watertown, Massachusetts, United States

Stage

Phase 2

Type

Therapeutics

Modalities

antibody · bispecific

Therapeutic area

Immunology · Dermatology · Respiratory

002Signature Detected

EVENT DETECTED

Event type

Phase 1 first-in-human dosing

Magnitude

First healthy volunteers dosed with TRIV-573, half-life extended KLK5/7×IL-13 bispecific; Phase 2 proof-of-concept in moderate-to-severe atopic dermatitis planned later in 2026

Lead

Triveni Bio (sponsor)

Participating

None disclosed

Use of capital

N/A (no financing event); program funded by prior $92M Series A (Oct 2023, Atlas/Cormorant co-led) and $115M Series B (Oct 2024, Goldman Sachs Alternatives led)

003Architecture

PLATFORM PROFILE

Target class

KLK5/7 + IL-13 (bispecific antibody combining serine protease inhibition with type 2 cytokine blockade)

Differentiator

Half-life extended bispecific that pairs the protease-only mechanism Triveni is already testing in TRIV-509 (Phase 2, n=90, NCT07167758) with IL-13 blockade in a single molecule. Targets two orthogonal arms of atopic dermatitis biology at once: barrier dysfunction (kallikreins) and Th2 inflammation (IL-13). Most extended half-life antibodies in AD hit IL-4Rα or IL-13 alone; Triveni is layering the barrier mechanism on top.

Lead asset

TRIV-573 (bispecific antibody, KLK5/7 × IL-13, half-life extended, Phase 1)

Pipeline depth

Two clinical AD assets: TRIV-509 (KLK5/7 mAb, Phase 2 POC in moderate-to-severe AD, n=90, readout end of 2026) and TRIV-573 (bispecific, Phase 1, Phase 2 POC planned later in 2026). Preclinical antibody against trypsin 1/2 for hereditary pancreatitis (PRSS1 mutations, ~10K US patients).

004Voyager Assessment

MACHINE-GENERATED

Triveni is now running both the protease-only and the dual-mechanism bet in atopic dermatitis at the same time. TRIV-509 hits Phase 2 readout at end of 2026. TRIV-573 starts dosing healthy volunteers today and moves to Phase 2 POC later this year. If the protease-only data lands clean, TRIV-573 becomes a combination-on-one-molecule upgrade. If TRIV-509 underdelivers, the bispecific is the fallback that adds IL-13. With more than $200M raised, Triveni can run both reads in parallel.

005Adjacent Structures

FRONTIER MAP

Apogee Therapeutics· extended half-life AD antibodiesAttovia Therapeutics· biparatopic nanobody AD bispecificsProteologix· AD bispecific acquired by JNJWindward Bio· long-acting respiratory/AD antibodiesConnect Biopharma· clinical AD/asthma pipelinePoplar Therapeutics· next-gen anti-IgE atopic diseaseAclaris Therapeutics· kinase plus antibody immunologySanofi· Dupixent IL-4Rα incumbent

— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.